ALXO · Insider Trading
ALX Oncology Holdings Inc. Common Stock
Every open-market purchase and sale reported by ALXO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | Sell | −2,230 | −$4.30K |
| 2026-08-18 | Shelly Wong | SVP, FINANCE AND CAO | Sell | −573 | −$1.11K |
| 2026-07-06 | Shelly Wong | SVP, FINANCE AND CAO | Sell | −1,404 | −$2.86K |
| 2026-04-17 | Jeff E. Knight | Chief Dev & Operating Officer | A | +800,000 deriv. | — |
| 2026-04-17 | Barbara Klencke | Chief Medical Officer | A | +100,000 deriv. | — |
| 2026-03-23 | Shelly Pinto | SVP, FINANCE AND CAO | Sell | −903 | −$1.96K |
| 2026-03-23 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | Sell | −12,311 | −$26.71K |
| 2026-03-05 | Barbara Klencke | Chief Medical Officer | A | +700,000 deriv. | — |
| 2026-02-20 | Shelly Pinto | SVP, FINANCE AND CAO | Sell | −565 | −$1.28K |
| 2026-02-19 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | F | −2,201 | −$5.00K |
| 2026-02-04 | Corey S Goodman | Director | Buy | +3,184,713 | +$5.00M |
| 2026-01-28 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | A | +912,000 deriv. | — |
| 2026-01-28 | Harish Shantharam | Chief Financial Officer | A | +303,000 deriv. | — |
| 2026-01-28 | Shelly Pinto | SVP, FINANCE AND CAO | A | +192,000 deriv. | — |
| 2026-01-21 | Rekha Hemrajani | Director | A | +40,400 deriv. | — |
| 2026-01-21 | Alan B. Sandler | Director | A | +10,100 deriv. | — |
| 2026-01-21 | J. Scott Garland | Director | A | +40,400 deriv. | — |
| 2026-01-21 | Daniel J. Curran | Director | A | +16,833 deriv. | — |
| 2026-01-21 | Corey S Goodman | Director | A | +40,400 deriv. | — |
| 2026-01-21 | Chris H Takimoto | Director | A | +40,400 deriv. | — |
| 2026-01-07 | Shelly Pinto | SVP, FINANCE AND CAO | Sell | −3,925 | −$4.36K |
| 2025-10-16 | Harish Shantharam | Chief Financial Officer | A | +198,750 deriv. | — |
| 2025-10-16 | Shelly Pinto | SVP, FINANCE AND CAO | A | +140,000 deriv. | — |
| 2025-10-16 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | A | +597,500 deriv. | — |
| 2025-09-19 | Barbara Klencke | Director | A | +300,000 deriv. | — |
| 2025-09-18 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | Buy | +92,233 | +$99.35K |
| 2025-08-20 | Harish Shantharam | Chief Financial Officer | Buy | +75,000 | +$58.40K |
| 2025-08-19 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | Sell | −2,382 | −$1.53K |
| 2025-08-19 | Shelly Pinto | SVP, FINANCE AND CAO | Sell | −611 | −$391 |
| 2025-08-13 | Daniel J. Curran | Director | A | +40,400 deriv. | — |
| 2025-07-08 | Shelly Pinto | SVP, FINANCE AND CAO | Sell | −2,011 | −$905 |
| 2025-07-01 | Shelly Pinto | SVP, FINANCE AND CAO | Sell | −1,532 | −$659 |
| 2025-04-15 | Harish Shantharam | Chief Financial Officer | A | +125,000 deriv. | — |
| 2025-04-15 | Alan B. Sandler | Chief Medical Officer | A | +125,000 deriv. | — |
| 2025-04-15 | Shelly Pinto | SVP, FINANCE AND CAO | A | +90,000 deriv. | — |
| 2025-04-15 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | A | +125,000 deriv. | — |
| 2025-03-18 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | A | +42,000 | — |
| 2025-03-18 | Shelly Pinto | SVP, FINANCE AND CAO | A | +3,000 | — |
| 2025-02-21 | Jaume Pons | PRESIDENT & CSO | Sell | −1,326 | −$1.53K |
| 2025-02-21 | Shelly Pinto | SVP, FINANCE AND CAO | Sell | −550 | −$633 |
| 2025-02-21 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | Sell | −2,159 | −$2.48K |
| 2025-01-23 | Chris H Takimoto | Director | A | +40,400 deriv. | — |
| 2025-01-23 | Alan B. Sandler | Chief Medical Officer | A | +100,000 deriv. | — |
| 2025-01-23 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | A | +478,000 deriv. | — |
| 2025-01-23 | J. Scott Garland | Director | A | +40,400 deriv. | — |
| 2025-01-23 | Corey S Goodman | Director | A | +40,400 deriv. | — |
| 2025-01-23 | Shelly Pinto | SVP, FINANCE AND CAO | A | +112,000 deriv. | — |
| 2025-01-23 | Barbara Klencke | Director | A | +40,400 deriv. | — |
| 2025-01-23 | Rekha Hemrajani | Director | A | +40,400 deriv. | — |
| 2025-01-23 | Harish Shantharam | Chief Financial Officer | A | +600,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jason Lettmann | CHIEF EXECUTIVE OFFICER | 2,317,848 | $2.62M |
| Jaume Pons | PRESIDENT & CSO | 579,388 | $654.71K |
| Corey S Goodman | Director | 113,287 | $128.01K |
| Shelly Wong | SVP, FINANCE AND CAO | 87,828 | $99.25K |
| Harish Shantharam | Chief Financial Officer | 75,000 | $84.75K |
| Rekha Hemrajani | Director | 33,000 | $37.29K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ALXO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.